Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 14/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 4/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL617233 | 0.92 | HTR5A (0.57) | HTR5AHTR7HTR2BSLC9A1 | |
| Hydrochloric Acid SCHEMBL617389 | 0.92 | HTR5A (0.56) | HTR5AHTR7HTR2BSLC9A1 | |
| SCHEMBL614952 | 0.91 | HTR5A (0.55) | HTR5AHTR7HTR2BSLC9A1 | |
| SCHEMBL10063692 | 0.90 | HTR5A (0.59) | HTR5AHTR7HTR2BSLC9A1CYP2D6 | |
| SCHEMBL10064314 | 0.89 | HTR5A (0.55) | HTR5AHTR7HTR2BSLC9A1 | |
| SCHEMBL616461 | 0.89 | HTR5A (0.56) | HTR5A | |
| SCHEMBL16503553 | 0.88 | HTR5A (0.50) | HTR5AHTR7HTR2BSLC9A1CYP2D6 | |
| SCHEMBL10063762 | 0.87 | HTR5A (0.44) | HTR5AHTR7HTR2BSLC9A1CYP2D6 | |
| SCHEMBL10064301 | 0.84 | HTR5A (0.43) | HTR5ASLC9A1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10063846 | 0.83 | SLC9A1 (0.42) | HTR5AHTR7HTR2BSLC9A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041036-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) | ASTELLAS PHARMA INC. (JP) | 2012-02-16 | — | — | US | claimed |
| EP-2394988-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-14 | — | — | EP | claimed |
| US-20120041036-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) | ASTELLAS PHARMA INC. (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120041036-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) | ASTELLAS PHARMA INC. (JP) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041036-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) | HTR5A, HTR2A, HTR1A | HTR5A 1/4885HTR7 11/4885HTR2B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.